DURGA-4

A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

  • 200822

Sorting 19 by

Sylvester Comprehensive Cancer Center
University of Miami
Coral Gables, FL
  • Not yet accepting
Huntsman Cancer Institute
University of Utah
Salt Lake City, UT
  • Accepting patients
Cleveland Clinic - Taussig Cancer Center
Taussig Cancer Institute
Cleveland, OH
  • Not yet accepting

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 864-8426

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.